



TRIO CASE STUDY SHOWING NOVEL MUTATION IN LAMB3 GENE CA JUNCTIONAL EPIDERMOLYSIS BULLOSA [INTERMEDIATE/SEVERE]

Srinadh B, Shaile Bandla, Soumya Peruchala

Asian Institute of Fetal Medicine And Reproductive Genetics -AIFMRG Trident Arafath Arcade, Road No. 10, opposite Star Hospitals, Banjara Hills, Hyderabad, Telangana

ABSTRACT

Background: Junctional epidermolysis Bullosa (JEB) is a type of Epidermolysis Bullosa, a group of genetic conditions that cause the skin to be very fragile and to blister easily. It is categorized into: the Herlitz type and the Non-Herlitz type. JEB is inherited in an autosomal recessive pattern. Most common genetic mutations associated are LAMB3, COL17A1, or LAMC2, and LAMA3 genes. **Case presentation:** This study reports a consanguineous couple carriers for pathogenic variant for LAMB3 gene, with an affected child with a homozygous mutation in the LAMB3 gene causing Herlitz type of Junctional epidermolysis Bullosa/ Non-Herlitz type of junctional epidermolysis bullosa. Furthermore, prenatal diagnosis for the Gravida also showed the same pathogenic variant. **Conclusion:** For autosomal recessive genetic conditions, it is advisable to perform genetic testing for the affected individual and further parental segregation which on whole considered as a Trio whole-exome sequencing or next-generation sequencing to detect the genes associated with the disease. Depending on the type of variants involved prenatal diagnosis for the next pregnancy and treatment or management (if available) options can be offered/discussed.

Keywords: Epidermolysis Bullosa; Skin blistering; Trio-exome sequencing; LAMB3; Trio study

INTRODUCTION

Junctional epidermolysis bullosa (JEB) is a group of heritable mechanobullous diseases characterized by blistering skin or tissue separation at the lamina lucida. This blistering could be due to little or no trauma. [1,2] EB affects the epithelial lining of the organs and is often termed the “butterfly children” as the skin of the younger individuals is said to be as fragile as a butterfly's wings. Worldwide, about 50 in 1 million live births are diagnosed with Epidermolysis bullosa (EB), out of these 92% are Epidermolysis bullosa simplex (EBS), 5% are Dystrophic epidermolysis bullosa (DEB), 1% is JEB and the rest 2% remains unknown. Incidence in India is estimated to be 54 per million live births (according to National Epidermolysis bullosa Registry) [3]. JEB is categorized into two different types Severe JEB (earlier known as Helitz JEB) and Intermediate JEB (earlier known as Non-Herlitz). The H-JEB variant is characterized by the early demise of the individuals affected usually within the first year of life with severe blistering of the skin over the large regions of the body, it could also affect the mucous membranes, such as the moist lining of the mouth and the digestive tract. On the other hand, nH-JEB shows milder phenotypic symptoms with life-long blistering with a normal life span. [4] As per OMIM three major genes LAMA3, LAMB3, and

LAMC2 that encode the subunit polypeptides of laminin -5 are associated with JEB. Out of which LAMB3 accounts for about 80% of all the laminin 5 mutations [5]. JEB represents a group of skin diseases that basically follows an autosomal recessive pattern of inheritance, in which the fetus or the children affected would be born to an obligate carrier parent who doesn't show any phenotypes of the disease [6]. The present study reports a boy child with a homozygous mutation in the LAMB3 gene causing Herlitz type of Junctional epidermolysis Bullosa/ Non-Herlitz type of junctional epidermolysis bullosa. Trio sequencing in a specific targeted population especially in cases of consanguineous families or the endogamous populations helps in identifying and understanding the autosomal recessive conditions. Henceforth the risk estimation for the next generations can be evaluated and accordingly the individuals can be guided in paving way for decision making.

CASE REPORT

A one-month-old boy born to a consanguineous couple presented with clinical indications of skin blistering and excoriation of the skin since birth. He is suspected to be affected with epidermolysis bullosa and has been evaluated for pathogenic variations. Henceforth, the index case was evaluated for whole-exome sequencing (WES) to identify the molecular and genetic basis of suspected genetic conditions. Selective capture and sequencing of the protein-coding regions of the genome/genes are performed. DNA extracted from blood was used to perform targeted gene capture using an exome capture kit. The



eISSN: 2583-7761

Correspondence: Srinadh.B Asian Institute of Fetal Medicine And Reproductive Genetics -AIFMRG Trident Arafath Arcade, Road No. 10, opposite Star Hospitals, Banjara Hills, Hyderabad, Telangana. srinadhb@gmail.com

libraries were sequenced to mean >80-100X coverage on Illumina sequencing platform. GATK best practices framework for identification of variants in the sample using Sentieon (v201808.07) was followed [7]. The WES analysis showed a homozygous four-base pair duplication in exon 18 of the LAMB3 gene (chr1:g.209618515dupAGCA; Depth: 150x) resulting in a frame shift and premature truncation of the protein 17 amino acids downstream to codon 950 (p.Ser950AlafsTer17; ENST00000391911.5) was detected. This variant in the LAMB3 gene was not reported earlier in the 1000 genomes, gnomAD, and the internal databases. However, based on the above evidence this LAMB3 variation is classified as a pathogenic variant. Going forward parental segregation was performed for the carrier status of pathogenic variants in the LAMB3 gene by Next generation sequencing (NGS). The targeted analysis revealed both the parents to be carriers of a pathogenic variant in the LAMB3 gene (p.Ser950AlafsTer17). However, the p.Ser950AlafsTer17 variant has not been reported in the 1000 genomes database and has a minor allele frequency of 0.006% in the internal database. Later on prenatal diagnosis was done for the fetus to evaluate for the same gene mutation. The fetus also presented with the pathogenic variant in the LAMB3 gene.

DISCUSSION

Intermediate junctional epidermolysis bullosa 1A (OMIM#226650) and Severe junctional epidermolysis bullosa 1B (OMIM#226700) are caused by homozygous or compound heterozygous mutations in the LAMB3 gene (OMIM*150310). Intermediate junctional epidermolysis bullosa 1A (JEB1A) is a blistering disease of the skin and mucous membranes. Generalized trauma-induced blistering occurs from birth. Blistering is less severe than in severe JEB, usually without the tendency for developing chronic granulation tissue. The plane of skin cleavage is through the lamina lucida of the cutaneous basement membrane zone. Nail dystrophy or loss and dental enamel defects are present. Scarring or non scarring alopecia and diffuse hair loss may occur. Blistering does not affect the life span of affected individuals. Severe junctional epidermolysis bullosa 1B (JEB1B) is a skin blistering disorder characterized by extreme fragility of the skin and epithelia of various extra cutaneous tissues. Blisters and erosions are present at birth. Blister formation occurs within the dermal-epidermal basement membrane zone [8,9]. The LAMA3, LAMB3, and LAMC2 genes each provide instructions for making one part (subunit) of a protein called laminin 332. Laminins are a family of network-forming trimeric proteins that are significant constituents of the basal lamina, an extracellular matrix layer of the basement membrane. Henceforth any mutations in these genes would be associated with the defective or non-functional version of the protein causing JEB [10-14].

As per the study by Aoi Nakano et al., we see mutations primarily found in the $\beta 3$ chain of the laminin 5, the LAMB3 gene is associated with the HEB. They studied the LAMB3 gene in about 22 families out of which 8 novel mutations were identified. Six out of 8 have created a downstream PTC (premature termination codon), and the other two showed an effect in the intron-exon borders potentially resulting in aberrant splicing [15]. As per the study by Aoi Nakano et al., 54 mutations were identified in a cohort of 24 patients, 22 of them novel. Mutations were identified in all three laminin 5 genes, with the majority in LAMB3. The common hotspot of LAMB3 gene, R365X is seen in 14 of 36 LAMB3 gene mutations. Thirteen of 15 Herlitz JEB patients were homozygous or compound heterozygotes for PTC mutations, while in eight of 12 non-Herlitz JEB patients a PTC mutation was combined with a missense or splicing mutation. The other four of non-HJEB showed compound heterozygous for PTC mutations [4].

CONCLUSION

In this study we did a Trio Exome sequencing (ES) initially for the affected child and later targeted analysis was performed in both the parents for the gene LAMB3 which is associated with Epidermolysis bullosa, Trio ES helps in aiding parental counseling and decision making in many cases. We have demonstrated that using medical trio ES followed by a targeted panel for prenatal diagnosis allows detection of autosomal recessive genetic conditions. Further which this helps in early detection and the management of the condition, if available.

Conflict of interest : No competing interests.

Source of funding : Nil

Acknowledgment : Support from Asian Institute of Fetal Medicine, Hyderabad is kindly acknowledged.

Authors Contribution: Shaile Bandla has conceived the idea, done with literature search, and wrote the initial draft, Srinadh.B provided the framework and edited the manuscript, Soumya Peruchala helped with the clinical data, Shaile Bandla contributed to the literature search, and finalized the manuscript. All the authors have read and approved the manuscript.

REFERENCES

1. Pulkkinen L, Meneguzzi G, McGrath JA, Xu Y, Blanchet-Bardon C, Ortonne JP, Uitto J. Predominance of the recurrent mutation R635X in the LAMB3 gene in European patients with Herlitz junctional epidermolysis bullosa has implications for mutation detection strategy. *J Invest Dermatol.* 1997;109(2):232-7.doi:10.1111/1523-1747.ep12319752
2. Laimer M, Lanschuetzer C, Diem A, Bauer JW. Herlitz junctional epidermolysis bullosa. *Dermatol*

- Clin. 2010;28(1):55-60. doi:10.1016/j.det.2009.10.006
3. Prasad V. Epidermolysis bullosae. Med J Armed Forces India. 2011;67(2):165-6. doi:10.1016/S0377-1237(11)60024-5
4. Nakano A, Chao SC, Pulkkinen L, Murrell D, Bruckner-Tuderman L, Pfindner E, et al. Laminin 5 mutations in junctional epidermolysis bullosa: molecular basis of Herlitz vs non-Herlitz phenotypes. Hum Genet. 2001;110(1):41-51. doi:10.1007/s00439-001-0630-1
5. Online Mendelian Inheritance in Man (OMIM). LAMB3 gene entry. Available from: <https://www.omim.org/entry/150310>
6. Yancey KB, Hintner H. Non-Herlitz junctional epidermolysis bullosa. Dermatol Clin. 2010;28(1):67-77. doi:10.1016/j.det.2009.10.008
7. Freed D, Aldana R, Weber JA, Edwards JS. The Sentieon Genomics Tools—a fast and accurate solution to variant calling from next generation sequence data. bioRxiv. 2017. doi:10.1101/115717
8. Online Mendelian Inheritance in Man (OMIM). Available from: <https://www.omim.org/>
9. Pfindner EG, Lucky AW. Junctional Epidermolysis Bullosa. 2008 Feb 22 [Updated 2018 Dec 20]. In: Adam MP, Feldman J, Mirzaa GM, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2025. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK1125/>
10. Poulter JA, El-Sayed W, Shore RC, Kirkham J, Inglehearn CF, Mighell AJ. Whole-exome sequencing, without prior linkage, identifies a mutation in LAMB3 as a cause of dominant hypoplastic amelogenesis imperfecta. Eur J Hum Genet. 2014;22(1):132-5. doi:10.1038/ejhg.2013.76
11. Michle C, Jiang QJ, Charlesworth A, Bruckner-Tuderman L, Meneguzzi G, Schneider H. Novel and recurrent mutations in the laminin-5 genes causing lethal junctional epidermolysis bullosa: molecular basis and clinical course of Herlitz disease. Hum Genet. 2004;116(1-2):33-42. doi:10.1007/s00439-004-1210-y
12. Christiano AM, Pulkkinen L, McGrath JA, Uitto J. Mutation-based prenatal diagnosis of Herlitz junctional epidermolysis bullosa. Prenat Diagn. 1997;17(4):343-54. PMID:9160387
13. Kivirikko S, McGrath JA, Pulkkinen L, Uitto J, Christiano AM. Mutational hotspots in the LAMB3 gene in the lethal (Herlitz) type of junctional epidermolysis bullosa. Hum Mol Genet. 1996;5(2):231-7. doi:10.1093/hmg/5.2.231
14. Sawamura D, Nakano H, Matsuzaki Y. Overview of epidermolysis bullosa. J Dermatol. 2010;37(3):214-9. doi:10.1111/j.1346-8138.2009.00800.x
15. Nakano A, Pfindner E, Pulkkinen L, Uitto J, Hashimoto I. Herlitz junctional epidermolysis bullosa: novel and recurrent mutations in the LAMB3 gene and the population carrier frequency. J Invest Dermatol. 2000;115(3):493-8. doi:10.1046/j.1523-1747.2000.00086.x